A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience

IF 2.7 3区 医学 Q3 ONCOLOGY
Dan Yao, Xueru Zhu, Jindong Guo, Xiaohuan Dong, Ya Zeng, Xiaolong Fu, Wen Yu
{"title":"A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience","authors":"Dan Yao,&nbsp;Xueru Zhu,&nbsp;Jindong Guo,&nbsp;Xiaohuan Dong,&nbsp;Ya Zeng,&nbsp;Xiaolong Fu,&nbsp;Wen Yu","doi":"10.1016/j.ctro.2024.100787","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>We aimed to assess the value of stereotactic body radiotherapy (SBRT) delivered under the situation of controlled or progressed disease during ICI therapy in advanced or recurrent NSCLC.</p></div><div><h3>Methods</h3><p>We retrospectively collected patients with advanced or recurrent NSCLC who received SBRT concurrently with ICI in our institution between January 2017 and December 2021. Patients were divided into two groups, including those for whom SBRT was delivered initially or to the residual tumors during the first- or later-line ICI treatment (Group 1), and those for whom SBRT was given to the progressed tumors irrespective of first- or later-line ICI treatment (Group 2).</p></div><div><h3>Results</h3><p>A total of 144 patients were included. With median follow-up duration of 25.6 (range: 3.6 to 56.2) months, median progression-free survival (PFS) was 13.7 (95 % CI: 10.4 to 17.1) months and median overall survival (OS) was 52.8 [95 % CI: 30.6 to not available (NA)] months. In Group 1 (n = 78), median PFS was 17.9 (95 % CI: 14.5 to 29.8) months while median OS was not reached and 5-year OS rate was 61.2 %. In Group 2 (n = 66), median PFS was 8.0 (95 % CI: 6.0 to 13.1) months and median OS was 30.6 (95 % CI: 21.5 to NA) months.</p></div><div><h3>Conclusions</h3><p>SBRT combined with ICI demonstrated favorable survival for advanced or recurrent NSCLC, delivered in a controlled-disease situation as well as to progressed diseases with salvage-intent. Future prospective studies are warranted to investigate the optimal SBRT dose regimen and appropriate combination strategy to synergize ICI.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100787"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000648/pdfft?md5=a0b3c255b1d62a53ea4b3eeffbbc8f12&pid=1-s2.0-S2405630824000648-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630824000648","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

We aimed to assess the value of stereotactic body radiotherapy (SBRT) delivered under the situation of controlled or progressed disease during ICI therapy in advanced or recurrent NSCLC.

Methods

We retrospectively collected patients with advanced or recurrent NSCLC who received SBRT concurrently with ICI in our institution between January 2017 and December 2021. Patients were divided into two groups, including those for whom SBRT was delivered initially or to the residual tumors during the first- or later-line ICI treatment (Group 1), and those for whom SBRT was given to the progressed tumors irrespective of first- or later-line ICI treatment (Group 2).

Results

A total of 144 patients were included. With median follow-up duration of 25.6 (range: 3.6 to 56.2) months, median progression-free survival (PFS) was 13.7 (95 % CI: 10.4 to 17.1) months and median overall survival (OS) was 52.8 [95 % CI: 30.6 to not available (NA)] months. In Group 1 (n = 78), median PFS was 17.9 (95 % CI: 14.5 to 29.8) months while median OS was not reached and 5-year OS rate was 61.2 %. In Group 2 (n = 66), median PFS was 8.0 (95 % CI: 6.0 to 13.1) months and median OS was 30.6 (95 % CI: 21.5 to NA) months.

Conclusions

SBRT combined with ICI demonstrated favorable survival for advanced or recurrent NSCLC, delivered in a controlled-disease situation as well as to progressed diseases with salvage-intent. Future prospective studies are warranted to investigate the optimal SBRT dose regimen and appropriate combination strategy to synergize ICI.

立体定向体放射治疗联合免疫疗法治疗晚期或复发性非小细胞肺癌(NSCLC)的真实世界分析:单中心经验
背景我们旨在评估在晚期或复发性NSCLC患者接受ICI治疗期间,在疾病得到控制或进展的情况下进行立体定向体放射治疗(SBRT)的价值。患者被分为两组,包括最初接受 SBRT 或在一线或二线 ICI 治疗期间对残留肿瘤进行 SBRT 的患者(第 1 组),以及无论一线或二线 ICI 治疗情况如何均对进展肿瘤进行 SBRT 的患者(第 2 组)。中位随访时间为25.6个月(范围:3.6至56.2个月),中位无进展生存期(PFS)为13.7个月(95 % CI:10.4至17.1个月),中位总生存期(OS)为52.8个月(95 % CI:30.6至不可用(NA))。第一组(78 人)的中位生存期为 17.9 个月(95 % CI:14.5 至 29.8 个月),中位 OS 未达到,5 年 OS 率为 61.2%。结论SBRT 联合 ICI 对晚期或复发性 NSCLC 有着良好的生存效果,既能在疾病控制的情况下进行,也能以挽救为目的对进展期疾病进行治疗。未来有必要开展前瞻性研究,探讨最佳的SBRT剂量方案以及与ICI协同作用的适当组合策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
5.30
自引率
3.20%
发文量
114
审稿时长
40 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信